Acesso livre
Acesso livre

Oftalmologia

Estudo randomizado | Tratamento tópico do edema macular diabético com uso de suspensão oftálmica de dexametasona.

12 Ago, 2022 | 17:54h

Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study – Acta Ophthalmologica

Comentário: Topical Dexamethasone Ophthalmic Suspension OCS-01 Effective in DME Treatment – HCP Live

 


Revisão sistemática | Trabeculoplastia a laser para glaucoma de ângulo aberto e hipertensão ocular.

12 Ago, 2022 | 17:26h

Laser trabeculoplasty for open‐angle glaucoma and ocular hypertension – Cochrane Library

Resumo: Laser trabeculoplasty for open-angle glaucoma – Cochrane Library

Estudo relacionado: Randomized Trial: Selective Laser Trabeculoplasty vs. Eye Drops for First-line Treatment of Ocular Hypertension and Glaucoma

 


M-A | Tratamento do glaucoma neovascular.

10 Ago, 2022 | 14:20h

A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice – Graefe’s Archive for Clinical and Experimental Ophthalmology

 


Estudo de coorte retrospectiva | Avaliação retrospectiva de desfechos oftalmológicos e neurológicos em bebês nascidos antes de 24 semanas de idade gestacional.

9 Ago, 2022 | 17:06h

Retrospective evaluation of ophthalmological and neurological outcomes for infants born before 24 weeks gestational age in a Swedish cohort – BMJ Open

 


M-A | Agonistas receptores de GLP1 estão associados com risco aumentado de progressão de retinopatia em pacientes com diabetes tipo 2.

4 Ago, 2022 | 14:26h

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link para o resumo – $ para o texto completo)

Comentário: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues

 


Global Retinoblastoma Outcome Study | Análise baseada em grupos e prospectiva de 4.064 pacientes de 149 países.

18 Jul, 2022 | 12:33h

The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries – The Lancet Global Health

Comentário convidado: Retinoblastoma as a lens for correctable disparities worldwide – The Lancet Global Health

Comunicado de imprensa: Children in low-income countries 16 times more likely to die from most common eye cancer – London School of Hygiene & Tropical Medicine

 


Estudo de coorte retrospectiva | Achados prognósticos de ressonância magnética para desfechos visuais e de mortalidade na rinossinusite fúngica invasiva aguda.

7 Jul, 2022 | 11:51h

Magnetic Resonance Imaging Prognostic Findings for Visual and Mortality Outcomes in Acute Invasive Fungal Rhinosinusitis – Ophthalmology


Revisão sistemática | Rituximabe para oftalmopatia associada a tireoide.

21 Jun, 2022 | 12:52h

Rituximab for thyroid‐associated ophthalmopathy – Cochrane Library

Resumo: What are the benefits and risks of rituximab (a medicine that reduces inflammation) for the treatment of thyroid-associated ophthalmopathy (a disease affecting the tissues surrounding the eyes) – Cochrane Library


Este paciente com conjuntivite infecciosa aguda tem uma infecção bacteriana? Revisão sistemática de exame clínico racional.

19 Jun, 2022 | 17:14h

Does This Patient With Acute Infectious Conjunctivitis Have a Bacterial Infection? The Rational Clinical Examination Systematic Review – JAMA (gratuito por tempo limitado)

 

Comentário no Twitter

 


Revisão sistemática | Inibidor da Rho-quinase para glaucoma primário de ângulo aberto e hipertensão ocular.

19 Jun, 2022 | 14:57h

Rho kinase inhibitor for primary open‐angle glaucoma and ocular hypertension – Cochrane Library

Resumo: Rho kinase inhibitors for primary open-angle glaucoma and ocular hypertension – Cochrane Library


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.